Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: Ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218

Giorgia Timon, Delia Ciardo, Alessia Bazani, Giulia Marvaso, Giulia Riva, Stefania Volpe, Damaris P. Rojas, Giuseppe Renne, Giuseppe Petralia, Dario Zerini, Cristiana Fodor, Samantha Dicuonzo, Davide Maestri, Floriana Pansini, Raffaella Cambria, Federica Cattani, Federica Golino, Valerio Scroffi, Daniela De Lorenzo, Ottavio De CobelliRoberto Orecchia, Barbara Alicja Jereczek-Fossa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

objective: To report preliminary results of a cutting edge extreme hypofractionated treatment with concomitant boost to the dominant lesion for patients with early stage prostate cancer (PCa). methods: AIRC-IG-13218 is a prospective Phase II trial started in June 2015. Patients with low and intermediate risk PCa who met the inclusion criteria underwent extreme hypofractionated radiotherapy to the prostate (36.25 Gy in 5 fractions) and a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) to 37.5 Gy. The DIL was identified by a multiparamentric MRI (mpMRI) co-registered with planning CT. Toxicity was assessed according to CTCAE v4.0 and RTOG/EORTC criteria. The preliminary evaluation of the first 13 patients was required to confirm the feasibility of the treatment before completing the enrollment of 65 patients. results: The first 13 patients completed the treatment between June 2015 and February 2016. With a median clinical follow-up of 17 months (range 11-26), no Grade 3 or 4 early toxicity was reported. Conclusions: Our preliminary data about early toxicity of an extreme hypofractionated schedule with concomitant boost on the DIL are encouraging. The higher number of patients expected for the trial and a longer follow-up are needed to confirm these results.

Original languageEnglish
Article number20160725
JournalBritish Journal of Radiology
Volume91
Issue number1089
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Prostatic Neoplasms
Radiotherapy
Prostate
Appointments and Schedules
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{c6ff9481130f459e9007dafebf15fc9a,
title = "Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: Ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218",
abstract = "objective: To report preliminary results of a cutting edge extreme hypofractionated treatment with concomitant boost to the dominant lesion for patients with early stage prostate cancer (PCa). methods: AIRC-IG-13218 is a prospective Phase II trial started in June 2015. Patients with low and intermediate risk PCa who met the inclusion criteria underwent extreme hypofractionated radiotherapy to the prostate (36.25 Gy in 5 fractions) and a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) to 37.5 Gy. The DIL was identified by a multiparamentric MRI (mpMRI) co-registered with planning CT. Toxicity was assessed according to CTCAE v4.0 and RTOG/EORTC criteria. The preliminary evaluation of the first 13 patients was required to confirm the feasibility of the treatment before completing the enrollment of 65 patients. results: The first 13 patients completed the treatment between June 2015 and February 2016. With a median clinical follow-up of 17 months (range 11-26), no Grade 3 or 4 early toxicity was reported. Conclusions: Our preliminary data about early toxicity of an extreme hypofractionated schedule with concomitant boost on the DIL are encouraging. The higher number of patients expected for the trial and a longer follow-up are needed to confirm these results.",
author = "Giorgia Timon and Delia Ciardo and Alessia Bazani and Giulia Marvaso and Giulia Riva and Stefania Volpe and Rojas, {Damaris P.} and Giuseppe Renne and Giuseppe Petralia and Dario Zerini and Cristiana Fodor and Samantha Dicuonzo and Davide Maestri and Floriana Pansini and Raffaella Cambria and Federica Cattani and Federica Golino and Valerio Scroffi and {De Lorenzo}, Daniela and {De Cobelli}, Ottavio and Roberto Orecchia and Jereczek-Fossa, {Barbara Alicja}",
year = "2018",
month = "1",
day = "1",
doi = "10.1259/bjr.20160725",
language = "English",
volume = "91",
journal = "British Journal of Radiology",
issn = "0007-1285",
publisher = "British Institute of Radiology",
number = "1089",

}

TY - JOUR

T1 - Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion

T2 - Ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218

AU - Timon, Giorgia

AU - Ciardo, Delia

AU - Bazani, Alessia

AU - Marvaso, Giulia

AU - Riva, Giulia

AU - Volpe, Stefania

AU - Rojas, Damaris P.

AU - Renne, Giuseppe

AU - Petralia, Giuseppe

AU - Zerini, Dario

AU - Fodor, Cristiana

AU - Dicuonzo, Samantha

AU - Maestri, Davide

AU - Pansini, Floriana

AU - Cambria, Raffaella

AU - Cattani, Federica

AU - Golino, Federica

AU - Scroffi, Valerio

AU - De Lorenzo, Daniela

AU - De Cobelli, Ottavio

AU - Orecchia, Roberto

AU - Jereczek-Fossa, Barbara Alicja

PY - 2018/1/1

Y1 - 2018/1/1

N2 - objective: To report preliminary results of a cutting edge extreme hypofractionated treatment with concomitant boost to the dominant lesion for patients with early stage prostate cancer (PCa). methods: AIRC-IG-13218 is a prospective Phase II trial started in June 2015. Patients with low and intermediate risk PCa who met the inclusion criteria underwent extreme hypofractionated radiotherapy to the prostate (36.25 Gy in 5 fractions) and a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) to 37.5 Gy. The DIL was identified by a multiparamentric MRI (mpMRI) co-registered with planning CT. Toxicity was assessed according to CTCAE v4.0 and RTOG/EORTC criteria. The preliminary evaluation of the first 13 patients was required to confirm the feasibility of the treatment before completing the enrollment of 65 patients. results: The first 13 patients completed the treatment between June 2015 and February 2016. With a median clinical follow-up of 17 months (range 11-26), no Grade 3 or 4 early toxicity was reported. Conclusions: Our preliminary data about early toxicity of an extreme hypofractionated schedule with concomitant boost on the DIL are encouraging. The higher number of patients expected for the trial and a longer follow-up are needed to confirm these results.

AB - objective: To report preliminary results of a cutting edge extreme hypofractionated treatment with concomitant boost to the dominant lesion for patients with early stage prostate cancer (PCa). methods: AIRC-IG-13218 is a prospective Phase II trial started in June 2015. Patients with low and intermediate risk PCa who met the inclusion criteria underwent extreme hypofractionated radiotherapy to the prostate (36.25 Gy in 5 fractions) and a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) to 37.5 Gy. The DIL was identified by a multiparamentric MRI (mpMRI) co-registered with planning CT. Toxicity was assessed according to CTCAE v4.0 and RTOG/EORTC criteria. The preliminary evaluation of the first 13 patients was required to confirm the feasibility of the treatment before completing the enrollment of 65 patients. results: The first 13 patients completed the treatment between June 2015 and February 2016. With a median clinical follow-up of 17 months (range 11-26), no Grade 3 or 4 early toxicity was reported. Conclusions: Our preliminary data about early toxicity of an extreme hypofractionated schedule with concomitant boost on the DIL are encouraging. The higher number of patients expected for the trial and a longer follow-up are needed to confirm these results.

UR - http://www.scopus.com/inward/record.url?scp=85052588610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052588610&partnerID=8YFLogxK

U2 - 10.1259/bjr.20160725

DO - 10.1259/bjr.20160725

M3 - Article

AN - SCOPUS:85052588610

VL - 91

JO - British Journal of Radiology

JF - British Journal of Radiology

SN - 0007-1285

IS - 1089

M1 - 20160725

ER -